Process Mass Intensity Calculator

PMI is always ≥ 1 (no negative values possible), is conceptually simpler (total input per unit output), and can be directly broken down into component contributions (solvents, reagents, etc.). E-factor can approach zero, which may give a misleading sense of near-perfection. Both convey the same information since PMI = E-factor + 1.

All materials that enter the process: starting materials, reagents, solvents (reaction and workup), catalysts (if not fully recovered), drying agents, filter aids, chromatographic media (if used), and water. Energy is not included in PMI but should be tracked separately. The boundary conditions should be clearly defined and reported.

Solvents typically dominate PMI, contributing 50-80% of total mass in pharmaceutical processes. Reaction solvents, extraction solvents, wash solvents, and chromatography mobile phases all add up. This is why solvent reduction, substitution, and recycling are the most effective strategies for reducing PMI.

The ACS GCI Pharmaceutical Roundtable has collected PMI data from member companies for hundreds of processes. Benchmarking compares a specific process against industry averages for similar complexity levels. The PMI Prediction Tool helps estimate expected PMI based on the number of synthetic steps, reaction types, and purification methods.

Yes. Step-wise PMI analysis reveals which steps consume the most material. The overall PMI is the sum of each step's contribution normalized by cumulative yield to that point. This analysis guides process improvement efforts toward the highest-impact steps.

If solvents are recycled, only the makeup solvent (fresh solvent added to replace losses) should be counted in PMI. For a process recycling 90% of its solvent, the effective solvent PMI contribution drops by 90%. Solvent recycling is often the single most effective strategy for reducing PMI in pharmaceutical manufacturing.

Biocatalytic processes often achieve lower PMI than chemical routes because they operate in water (which may be excluded from PMI), use mild conditions (less energy), and can be highly selective (less purification needed). The Merck biocatalytic route to sitagliptin reduced PMI by 60% compared to the original chemical synthesis.

Continuous flow manufacturing typically reduces PMI by 20-50% compared to batch processing. Benefits include: smaller reactor volumes (less solvent), better heat/mass transfer (higher selectivity), in-line purification (less wash solvent), and real-time monitoring for optimal conditions. The steady-state operation also reduces startup waste.

PMI and carbon footprint are related but not equivalent. PMI tracks mass; carbon footprint tracks greenhouse gas emissions. Solvent recycling reduces PMI but requires energy (increasing carbon footprint). Complete lifecycle assessment (LCA) accounts for both material and energy impacts. However, reducing PMI almost always reduces carbon footprint because waste treatment and material production are energy-intensive.